Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction of Uptravi 200mcg Tablets:
Uptravi 200mcg Tablet contains selexipag, a medication used in the treatment of pulmonary arterial hypertension (PAH). It was approved by the U.S. Food and Drug Administration (FDA) in December 2015. PAH is a condition characterized by high blood pressure in the arteries of the lungs, which can lead to heart failure and other serious health problems. Selexipag belongs to a class of drugs known as prostacyclin receptor agonists and is designed to help manage the symptoms and slow the progression of PAH.
Uses of Uptravi 200mcg Tablets:
Pulmonary Arterial Hypertension (PAH)
Benefits of Uptravi 200mcg Tablets:
In Pulmonary Arterial Hypertension Management:
Uptravi 200mcg Tablet is primarily used for the treatment of PAH. PAH is a rare and potentially life-threatening condition in which the arteries that supply blood to the lungs become narrowed and constricted. This causes increased pressure in the pulmonary arteries, making it more difficult for the heart to pump blood through the lungs. Uptravi helps to manage the symptoms of PAH, such as shortness of breath, fatigue, and chest pain. It can also slow the progression of the disease, improving the patient's overall quality of life.
Mechanism of Action of Uptravi 200mcg Tablets:
Uptravi 200mcg Tablet exerts its effects by binding to and activating the prostacyclin receptor (IP receptor) in the body. Prostacyclin is a natural substance that helps to relax and widen blood vessels and inhibit the proliferation of smooth muscle cells in the arterial walls. This mechanism of action helps to reduce pulmonary arterial pressure and improve blood flow in patients with PAH.